Columbia researchers have shined new light on how the “dark” part of the genome allows cancer cells to be detected by the immune system, which could lead to better immunotherapies.
Columbia’s researchers have opened a trial of a noninvasive, focused ultrasound approach to open the blood-brain barrier, enabling higher concentrations of an effective drug to enter the brain.
Dr. Drake studies the body’s immunological response to radiation therapy and how immunotherapy and radiation therapy can be used in concert to treat cancer.
Adding a new drug called olaratumab to traditional chemotherapy increased survival in sarcoma patients, researchers at Columbia University Medical Center have found.
The three-dimensional structure could help researchers develop novel therapies and diagnostic tools for diseases that are caused by a malfunction in calcium adsorption.
According to a new report published in JAMA Oncology, women with BRCA1 mutations have a higher risk of developing an aggressive type of uterine cancer.
$4 million grant gives Columbia, Weill Cornell Medicine, NewYork-Presbyterian, and NYC Health + Hospitals key role in precision medicine cohort program.
Cancer centers announce the establishment of a research consortium focused on accelerating the discovery and development of novel cancer therapeutics and diagnostics for the benefit of patients.